Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 3Phase 1/2 3Phase EARLY_PHASE1 1Phase 3 1Phase 2/3 1

Status

Terminated 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Multiple Myeloma 337Neoplasms, Plasma Cell 56Precursor Cell Lymphoblastic Leukemia-Lymphoma 54Recurrence 50Lymphoma 48Leukemia 39Neoplasms 27Lymphoma, Mantle-Cell 27Burkitt Lymphoma 26Lymphoma, Large B-Cell, Diffuse 23Immunoglobulin Light-chain Amyloidosis 23Lymphoma, Non-Hodgkin 22Waldenstrom Macroglobulinemia 21Lymphoma, Follicular 17Leukemia, Lymphocytic, Chronic, B-Cell 16Hodgkin Disease 14Nausea 12Lymphoma, Extranodal NK-T-Cell 12Lymphoma, B-Cell, Marginal Zone 12Vomiting 11Smoldering Multiple Myeloma 11Prostatic Neoplasms 11Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 11Breast Neoplasms 11Renal Insufficiency 10Neoplasm Metastasis 9Lymphoma, Large-Cell, Immunoblastic 9Carcinoma, Non-Small-Cell Lung 9Lung Neoplasms 8Leukemia, Biphenotypic, Acute 7

Interventions

Rituximab 45Cyclophosphamide 34Doxorubicin 16fludarabine 14Prednisone 14Vincristine 13Etoposide 13ibrutinib 10Mycophenolic Acid 8Bortezomib 8Magnetic Resonance Spectroscopy 7Lenalidomide 7Cytarabine 7pembrolizumab 6Immunotherapy, Adoptive 6polatuzumab vedotin 5fludarabine phosphate 5Whole-Body Irradiation 5Vorinostat 5Tacrolimus 5Specimen Handling 5CT-P10 5obinutuzumab 4ibritumomab tiuxetan 4Nivolumab 4Ifosfamide 4Carmustine 4Carboplatin 4Antilymphocyte Serum 4tafasitamab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma, B-Cell × Dexamethasone × Clear all
NCT07588698 2026-05-15

Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma

University of California, San Francisco

Phase 2 Not yet recruiting
20 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT00290498 2020-06-02

Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger

M.D. Anderson Cancer Center

Phase 2 Completed
67 enrolled 12 charts
Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT00413959 2018-09-19

VRCD

Oncology Specialists, S.C.

Phase 2 Terminated
12 enrolled 7 charts
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡